Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lifeward Ltd.LFWD · Entity 7620 | Interim CEO | September 01, 2026 | September 01, 2026 |
| ORAMED PHARMACEUTICALS INC.ORMP · Entity 6311 | COO & CBO | October 01, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lifeward Ltd.
Report date September 01, 2026 · Filed September 01, 2026
This filing explicitly reported no securities owned.
ORAMED PHARMACEUTICALS INC.
Report date October 01, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,328,130 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Sale · Disposed 30,000 · Balance 1,328,130 F1: Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.440 to $4.650, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.440 to $4.650, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 2, 2026 21:19 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | SaleCommon Stock | 30,000 | $4.51 | $135,330.00 |
DisclosureSEC source: 0001213900-26-106530 · ownership.xml · nonDerivative · entry 1 Hexter Joshua · CIK 0001573235 · COO & CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,328,130 F1 · shares: Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.440 to $4.650, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:31 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Disposition to issuerStock option (right to buy) · Derivative | 36,000 | Not disclosed Strike: $13.89 | Not disclosed |
DisclosureSEC source: 0001213900-26-103538 · ownership.xml · derivative · entry 5 Hexter Joshua · CIK 0001573235 · COO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,000 shares Expires 2032-01-03 F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 75,455 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. F5 · derivative.exercise_date: The canceled option provided for vesting in 4 equal installments as follows: 9,000 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:31 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Disposition to issuerStock option (right to buy) · Derivative | 50,000 | Not disclosed Strike: $10.40 | Not disclosed |
DisclosureSEC source: 0001213900-26-103538 · ownership.xml · derivative · entry 4 Hexter Joshua · CIK 0001573235 · COO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2031-02-03 F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 75,455 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. F4 · derivative.exercise_date: The canceled option provided for vesting in 4 equal installments as follows: 12,500 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:31 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Disposition to issuerStock option (right to buy) · Derivative | 50,000 | Not disclosed Strike: $3.69 | Not disclosed |
DisclosureSEC source: 0001213900-26-103538 · ownership.xml · derivative · entry 3 Hexter Joshua · CIK 0001573235 · COO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2029-09-11 F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 75,455 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. F3 · derivative.exercise_date: The canceled option provided for vesting in 16 equal installments of 6,250 on the first day of every three-month period beginning November 1, 2019. Of the vested options, 50,000 were previously exercised. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:31 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 209,291 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-26-103538 · ownership.xml · nonDerivative · entry 2 Hexter Joshua · CIK 0001573235 · COO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,358,130 F2 · price: On September 24, 2026, the issuer granted to the reporting person a restricted stock award of an aggregate of 209,291 shares pursuant to the issuer's Amended and Restated 2019 Stock Incentive Plan (the "Plan"). The restricted stock vests as to forty percent (40%) on the date of grant and as to the remaining sixty percent (60%) in eight (8) substantially equal quarterly installments over the twenty-four (24) month period following the date of grant, subject to the reporting person's continued service with the issuer. Unvested shares are subject to forfeiture in accordance with the terms of the applicable award agreement and the Plan. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:31 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 75,455 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-26-103538 · ownership.xml · nonDerivative · entry 1 Hexter Joshua · CIK 0001573235 · COO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,148,839 F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 75,455 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. Read SEC document |
| July 02, 2026 Filed Jul 2, 2026 21:00 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Exercise / conversionStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.69 | $0.00 |
DisclosureSEC source: 0001213900-26-075070 · ownership.xml · derivative · entry 3 Hexter Joshua · CIK 0001573235 · COO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options vested and became exercisable in 16 equal installments of 6,250 on the first day of every three-month period beginning November 1, 2019. Read SEC document |
| July 02, 2026 Filed Jul 2, 2026 21:00 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Exercise / conversionCommon Stock | 50,000 | $3.69 | $184,500.00 |
DisclosureSEC source: 0001213900-26-075070 · ownership.xml · nonDerivative · entry 2 Hexter Joshua · CIK 0001573235 · COO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,073,384 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 21:00 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | SaleCommon Stock | 137,000 | $4.46 | $611,431.00 |
DisclosureSEC source: 0001213900-26-075070 · ownership.xml · nonDerivative · entry 1 Hexter Joshua · CIK 0001573235 · COO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,023,384 F1 · shares: Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.255 to $4.7652, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 21:46 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 95,889 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-031012 · ownership.xml · nonDerivative · entry 1 Hexter Joshua · CIK 0001573235 · COO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,160,384 F1 · shares: Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer. F1 · price: Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer. Read SEC document |
| January 22, 2026 Filed Jan 29, 2026 21:05 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Exercise / conversionPerformance Stock Units · Derivative | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-009477 · ownership.xml · derivative · entry 2 Hexter Joshua · CIK 0001573235 · COO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents the vesting of performance stock units ("PSUs") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share ("Common Stock"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting. F2 · derivative.exercise_date: Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria. F2 · derivative.expiration_date: Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria. Read SEC document |
| January 22, 2026 Filed Jan 29, 2026 21:05 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Exercise / conversionCommon Stock | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-009477 · ownership.xml · nonDerivative · entry 1 Hexter Joshua · CIK 0001573235 · COO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,064,495 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of performance stock units ("PSUs") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share ("Common Stock"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting. F1 · price: Represents the vesting of performance stock units ("PSUs") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share ("Common Stock"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 22:20 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantPerformance Stock Units · Derivative | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-001278 · ownership.xml · derivative · entry 3 Hexter Joshua · CIK 0001573235 · COO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires not disclosed F3 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria. F3 · derivative.exercise_date: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria. F3 · derivative.expiration_date: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 22:20 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 115,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-001278 · ownership.xml · nonDerivative · entry 2 Hexter Joshua · CIK 0001573235 · COO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,045,495 F2 · shares: Represents RSUs that will vest in quarterly installments over a three-year period starting January 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer. F2 · price: Represents RSUs that will vest in quarterly installments over a three-year period starting January 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 22:20 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 97,328 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-001278 · ownership.xml · nonDerivative · entry 1 Hexter Joshua · CIK 0001573235 · COO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 930,495 F1 · shares: Represents Restricted Stock Units ("RSUs") that vested in full on January 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share ("Common Stock"), of the Issuer. F1 · price: Represents Restricted Stock Units ("RSUs") that vested in full on January 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share ("Common Stock"), of the Issuer. Read SEC document |
| February 11, 2025 Filed Feb 11, 2025 21:31 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 33,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-012240 · ownership.xml · nonDerivative · entry 3 Hexter Joshua · CIK 0001573235 · COO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 833,167 F3 · shares: Represents shares issued on settlement of PSUs previously granted on February 3, 2025 that vested on February 11, 2025 based on the achievement of the applicable performance criteria. Read SEC document |
| February 11, 2025 Filed Feb 11, 2025 21:31 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 48,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-012240 · ownership.xml · nonDerivative · entry 2 Hexter Joshua · CIK 0001573235 · COO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 799,833 F2 · shares: Represents shares issued on settlement of PSUs previously granted on January 2, 2025 that vested on February 11, 2025 based on the achievement of the applicable performance criteria. Read SEC document |
| February 11, 2025 Filed Feb 11, 2025 21:31 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-012240 · ownership.xml · nonDerivative · entry 1 Hexter Joshua · CIK 0001573235 · COO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 751,333 F1 · shares: Represents shares issued on settlement of performance stock units ("PSUs") previously granted on January 4, 2024 that vested on February 11, 2025 based on the achievement of the applicable performance criteria. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:10 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 194,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-25-001165 · ownership.xml · nonDerivative · entry 1 Hexter Joshua · CIK 0001573235 · COO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 706,333 F1 · price: Represents Restricted Stock Units ("RSUs") that will vest in quarterly installments of approximately 16,208 over a three year period starting January 1, 2025. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
| November 07, 2024 Filed Nov 8, 2024 21:30 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-24-095929 · ownership.xml · nonDerivative · entry 1 Hexter Joshua · CIK 0001573235 · COO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 511,833 F1 · price: Represents Restricted Stock Units ("RSUs") that will vest on November 7, 2024. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 21:40 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 180,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-001148 · doc4.xml · nonDerivative · entry 1 Hexter Joshua · CIK 0001573235 · COO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 481,833 F1 · price: Represents Restricted Stock Units ("RSUs") that will vest in quarterly installments of approximately 15,042 over a three year period starting January 8, 2024. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
| May 26, 2023 Filed May 31, 2023 21:10 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 27,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-033142 · doc4.xml · nonDerivative · entry 1 Hexter Joshua · CIK 0001573235 · COO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 301,333 F1 · price: Restricted Stock Units ("RSUs") granted in April 2023 and vested upon achievement of certain performance conditions. The RSUs converted into Issuer's common stock on a one-for-one basis. Read SEC document |
| April 17, 2023 Filed Apr 20, 2023 10:00 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 108,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-024940 · doc4.xml · nonDerivative · entry 1 Hexter Joshua · CIK 0001573235 · COO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 274,333 F1 · price: Represents Restricted Stock Units ("RSUs") that will vest in equal quarterly installments of 9,000 over a three year period starting May 1, 2023. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
| July 28, 2022 Filed Aug 2, 2022 00:00 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 42,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-043767 · doc4.xml · nonDerivative · entry 1 Hexter Joshua · CIK 0001573235 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,333 F1 · price: Represents Restricted Stock Units ("RSUs") that will vest in 3 installments as follows: 14,000 shall vest on each of January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 01:33 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $13.89 | $0.00 |
DisclosureSEC source: 0001213900-22-000807 · ownership.xml · derivative · entry 2 Hexter Joshua · CIK 0001573235 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2032-01-03 F2 · derivative.exercise_date: The Stock Option will vest in 4 installments as follows: 9,000 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 01:33 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 21,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-22-000807 · ownership.xml · nonDerivative · entry 1 Hexter Joshua · CIK 0001573235 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,333 F1 · price: Represents Restricted Stock Units ("RSUs") that will vest in 4 installments as follows: 5,250 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 20:46 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 33,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-21-046410 · ownership.xml · nonDerivative · entry 1 Hexter Joshua · CIK 0001573235 · Chief Operating & BO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,333 F1 · price: Restricted Stock Units ("RSUs") granted in February 2021 and vested upon achievement of certain vesting conditions. The RSUs convert into Issuer's common stock on a one-for-one basis. Read SEC document |
| February 03, 2021 Filed Feb 8, 2021 22:29 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $10.40 | $0.00 |
DisclosureSEC source: 0001213900-21-007497 · ownership.xml · derivative · entry 1 Hexter Joshua · CIK 0001573235 · COO, Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-02-03 F1 · kind: The Stock Option will vest in 4 equal installments as follows: 12,500 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024. F1 · derivative.exercise_date: The Stock Option will vest in 4 equal installments as follows: 12,500 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024. Read SEC document |
| September 12, 2019 Filed Sep 16, 2019 22:04 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.69 | $0.00 |
DisclosureSEC source: 0001213900-19-018196 · ownership.xml · derivative · entry 1 Hexter Joshua · CIK 0001573235 · Chf. Op. & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-09-12 F1 · derivative.exercise_date: The Stock Options will vest in 16 equal installments of 6,250 on the first day of every three month period beginning November 1, 2019. Read SEC document |
| May 03, 2018 Filed May 7, 2018 20:51 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock option (right to buy) · Derivative | 30,000 | $0.00 Strike: $6.70 | $0.00 |
DisclosureSEC source: 0001213900-18-005618 · f4050318hexter_oramedpharm.xml · derivative · entry 1 Hexter Joshua · CIK 0001573235 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-05-03 F1 · derivative.exercise_date: The Stock Option will vest in 16 equal installments of 1,875 on the last day of each quarter commencing June 30, 2018. Read SEC document |
| April 08, 2018 Filed Apr 10, 2018 21:41 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock option (right to buy) · Derivative | 30,000 | $0.00 Strike: $7.05 | $0.00 |
DisclosureSEC source: 0001213900-18-004250 · f4040818hexter_oramedpharm.xml · derivative · entry 1 Hexter Joshua · CIK 0001573235 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-04-08 F1 · derivative.exercise_date: The Stock Option will vest in 4 equal installments of 7,500 on each of April 1, 2019, April 1, 2020, April 1, 2021 and April 1, 2022. Read SEC document |
| November 01, 2016 Filed Nov 22, 2016 20:35 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 70,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-16-018868 · f4110116hexter_oramedpharma.xml · nonDerivative · entry 1 Hexter Joshua · CIK 0001573235 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 F1 · date: The shares vest as follows: 9,000 shares vest immediately; 1,500 shares will vest in 18 consecutive installments on the last day of each month commencing November 30, 2016; and 17,000 will vest in each of April 30, 2017 and April 30, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.